Oral monitoring of a pediatric patient during chemotherapy treatment

Monitoreo oral de un paciente pediátrico durante el tratamiento de quimioterapia

Isabella Lima Arrais Ribeiro,¹ Ana Maria Gondim Valença,¹ Paulo Rogério Ferreti Bonan,¹ Fabiola Galbiatti de Carvalho Carlo¹

¹ Departament of Statistic, Federal University of Paraiba, João Pessoa, Brazil.

ABSTRACT

Oral side effects must be expected during cancer treatment on pediatric patients. Monitoring side effects on oral cavity of antineoplastic therapy is desirable but sometimes performed without criteria. The purpose of this article is to describe an oral monitoring in an male with Hodgkin lymphoma during chemotherapy treatment using an Oral Assessment Guide. An 11-yr-old male was assisted during all treatment of chemotherapy against Hodgkin's lymphoma in the dental sector of a hospital of reference of João Pessoa, Paraíba, Brazil. The Oral Assessment Guide was applied by a calibrate examiner and was observed the emergence of ulcerative lesions on the labial mucosa emerged on two different periods (D15- primary cycle; D15- second cycle) and the major values of oral mucositis were verified in D1 e D15 periods of second cycle of chemotherapy. Monitoring oral side effects during antineoplastic therapy could prevent severe oral complications and avoid to associate systemic complications.

Key words: Hodgkin lymphoma, pediatric cancer, oral mucositis.

INTRODUCTION

Patients with leukemia or lymphoma undergoing chemotherapy frequently develop alterations of the oral cavity.¹ A direct effect of the drug on the oral mucosa or the associated myelosuppressive action are the two main mechanisms associated with side effects such as mucositis, dry
mout, bleeding, bone alterations, teeth disorders, pain and infections.¹⁻³
An ongoing oral assessment must be performed to promote the early identification of oral complications.

The purpose of this article is to describe an oral monitoring in an 11 year-old male with Hodgkin lymphoma during chemotherapy treatment using a modified Oral Assessment Guide.

**DESCRIPTION OF CASE**

An 11 year-old, male, non caucasian patient was referred to reference hospital on Paraiba state, Brazil, with initial complaint of a swelling on the right supraclavicular with progressive growth. Lymph node biopsy was taken revealing Hodgkin Lymphoma withpositiveness to EBV and sparse immunostaining to CD30. Therapy with chemotherapy administration was instituted following the protocol: 26 mg of Doxorubicin - IV for 30 min (D1 and D15), 10 mg of Bleomycin - IV for 30 min (D1 and D15); 6 mg of Vimblastein (IV push) (D1 and D15); 375 mg of Dacarbazine - IV for 120 min (D1 and D15) with a total of 5 cycles. Moreover, it was prescribed Sulfamethoxazole + Trimethoprim suspension orally for 12/12 h, 3 times per week in continuous use. The general recorder of patient evolution during chemotherapy is described on table 1.

At diagnosis, we evaluated the oral cavity and DMFT was equal to 3, due to the presence of two teeth restored without caries (permanent maxillary right second molar and primary mandibular right first molar), with restored before the antineoplastic treatment and a restored tooth with dental caries (primary mandibular right second molar). Need to improve daily oral hygiene was percept, which has been shown and monitored throughout treatment.

---

Table 1. General data focusing general side effects and clinical evolution of disease

<table>
<thead>
<tr>
<th>Cycle</th>
<th>Doses</th>
<th>Day</th>
<th>Systemic reactions</th>
<th>Evolution</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>D1</td>
<td>2 Feb 13</td>
<td>Vomited once after chemotherapy</td>
<td>Baseline</td>
</tr>
<tr>
<td></td>
<td>D15</td>
<td>20 Feb 13</td>
<td>Without complain</td>
<td>None</td>
</tr>
<tr>
<td>2</td>
<td>D1</td>
<td>19 Mar 13</td>
<td>Without complain</td>
<td>Cervical nodes less than 1 cm</td>
</tr>
<tr>
<td></td>
<td>D15</td>
<td>2 Apr 13</td>
<td>Without complain</td>
<td>Cervical nodes less than 1 cm</td>
</tr>
<tr>
<td>3</td>
<td>D1</td>
<td>30 Apr 13</td>
<td>Without complain</td>
<td>Absence of palpable cervical nodes</td>
</tr>
<tr>
<td></td>
<td>D15</td>
<td>14 May 13</td>
<td>Without complain</td>
<td>Absence of palpable cervical nodes</td>
</tr>
<tr>
<td>4</td>
<td>D1</td>
<td>28 May 13</td>
<td>Without complain</td>
<td>Absence of palpable cervical nodes</td>
</tr>
<tr>
<td></td>
<td>D15</td>
<td>11 Jun 13</td>
<td>Without complain</td>
<td>Absence of palpable cervical nodes</td>
</tr>
<tr>
<td>5</td>
<td>D1</td>
<td>25 Jun 13</td>
<td>Without complain</td>
<td>Absence of palpable cervical nodes</td>
</tr>
<tr>
<td></td>
<td>D15</td>
<td>9 Jul 13</td>
<td>Epigastric pain</td>
<td>Absence of palpable cervical nodes</td>
</tr>
</tbody>
</table>

---

A previous instrument used developed by Nebraska University, the Oral Assessment Guide (OAG) showed as a comprehensive, accurate tool for assessing oral integrity in children with cancer during and after chemotherapy.¹ The OAG is a guide of oral evaluation initially proposed by Eilers, Peterson and Berger in 1988⁴ and modified for Cheng et al. (2004)⁵ to assess changes in the oral mucosa resulting from antineoplastic treatment using chemotherapy. This instrument allows to evaluate 8 items, according to the scales of impaired oral health, with assigned values 1-3 for each item, as follows: 1 for conditions where it is checked normality; 2, for the verification of mild to moderate changes in relation to the epithelial integrity or function and 3 for a severe impairment. At the end, the total checked for mucositis varies from 8 to 24, without a cutoff between these values for the estimation of mucositis.
During the treatment, OAG was applied by a calibrated examiner during D1 and D15, inside the cycles, and the obtained values are described on table 2. On this index, we assigned a value of 1 to 3, according to the progressive morbidity.

During the assessments, ulcerative lesions on the labial mucosa emerged on two different periods (12 Mar 13 and 2 Apr 13) (Fig.). These mucositis events were coincident with higher levels of OAG. Palliative treatment for these two episodes of mucositis was the application of mucolaser (ECCO Fibras e Dispositivos/Brazil; n/s – 040401; model – BM0004A; Power – 120 Mw; Doses – 7 J/cm²; Time doses – 33 sec.) with clinical improvement.

**DISCUSSION**

The mucositis induced by chemotherapy occurs because during the primary damage response phase is initiate a series of interacting biological events as the activation of a number transcription factors, such as NF-KB, Wnt, P-53 and their associated cronical pathways. Each cycle of chemotherapy incurs in increased risk to develop mucositis.

Thus, monitoring the oral health of the patient, and the use of palliative treatments are needed to prevent injuries that might compromise the pediatric patients in antineoplastic therapy of cancer. Such monitoring can be done using the OAG, which allows the monitoring of different locations where mucositis can occur in the oral cavity.
Monitoring oral side effects during antineoplastic therapy could prevent severe oral complications and avoid to associate systemic complications and we recommended OAG, which proved to be efficient on detect mucositis upset and other oral alterations on oral cavity caused by chemotherapy.

REFERENCIAS BIBLIOGRÁFICAS


